|
|
|
|
|
|
|
Recent Events
02.05.10: Daniel Selvig Attends 2010 Highlights of ASH Meeting in San Francisco
Daniel Selvig, Consultant at Health Advances, represented Health Advances at the 2010 Highlights of ASH Meeting February 5-6, 2010. The meeting will feature leading hematology experts who will present analysis of the ASH annual meeting abstracts, evolving therapies, and the latest treatment options. In addition, daily panel discussions and programs such as “Breakfast with the Experts” will provide the opportunity to discuss real patient cases with leaders in the field, gain knowledge that can impact patient care strategies, and network with colleagues.
 learn more about our expertise in Oncology and Hematology.
01.30.10: Skip Irving Moderates Panel at HBS
Skip Irving, Partner and Managing Director at Health Advances, moderated a panel at Harvard Business School’s 2010 Healthcare
Conference. The panel, presented by the Healthcare Club at HBS, was entitled “Venture Capital & Entrepreneurship — Will Policy
Changes Kill Innovation in Healthcare?” Joining Skip on the panel were:
Bonnie Fendrock, President and CEO, Hepregen Corporation
Jeffrey Levin-Scherz, Principal, Towers Perrin
Tom McKinley, General Partner, Cardinal Partners
12.10.09: Kristin Pothier Participates in BIOMEDevice Forum in San Jose
In recent months, DTC genomics has been under intense scrutiny. Kristin Pothier, Vice President, Health Advances,
addressed this topic on December 10th at the 2009 BIOMEDevice Forum in San Jose, CA. She was joined
by Amy DuRoss, Vice President of Policy and Business Affairs, Navigenics; Leah Sparks, Sr. Director, Business
Development, DNA Direct; and Sandra Lee, Ph.D. Senior Research Scholar, Stanford University. The panelists
discussed how each has navigated through the regulatory, ethical, and business issues surrounding direct-to-consumer
diagnostics, what their greatest drivers and barriers are today, and how these controversial offerings may change
in the future.
learn about Health Advances’ expertise in diagnostics and discovery tools and read our latest publications.
12.03.09: Marie Schiller and Skip Irving Participate in Faster Cures Conference
Marie Schiller, Partner, and Skip Irving, Partner and
Managing Director, represented Health Advances at the FasterCures conference in New York
City. “Partnering for Cures” was a first-of-its-kind meeting that brought together philanthropy,
medical research foundations, and the biopharmaceutical industry in an effort to forge strategic
collaborations key to the timely development of new medical solutions. In addition to attending the conference,
Marie Schiller participated in a panel discussion entitled “Stories from the Front Lines of Philanthropy.”
Panel members shared their thoughts on philanthropic investment and collaboration in the battle to conquer
deadly diseases.
Speakers
Dana Ball, Program Director
David Panzirer - Trustee
Melissa Berman, CEO & President for Rockefeller Philanthropy Advisors
Marie Schiller, Partner – Health Advances
Doug Melton, Harvard Stem Cell Institute
Alan Lewis, CEO - JDRF
11.10.09: Paula Ness Speers attends Major Orthopedics Meeting in San Francisco (NASS)
Paula Ness Speers, Partner and Managing Director at Health Advances, participated in the annual meeting of the North American Spine Society in San Francisco during the week of November
10th. Health Advances has extensive experience in orthopedics. We have worked with clients on a variety of projects such as new
product design assessments, market sizing for new orthopedic products, and pricing and reimbursement strategies prior to market
launch. The firm also supports major transactions for strategic and financial clients interested in orthopedics products or
companies by conducting due diligence for licensing or acquisition activities.
Paula oversees the majority of our work in the orthopedic sector and can be reached by calling the firm’s Boston area office at 781-647-3435.
11.09.09: Health Advances Hosts VIP Reception for Executives interested in Vaccines and Global Health at the Broad Institute, Cambridge, MA
Health Advances hosted a VIP reception for approximately 80 executives interested in better understanding opportunities for vaccines in the global
health arena on November 9th at the Broad Institute in Cambridge. The reception preceded the MIT Enterprise Forum’s program titled: Vaccines & Global
Health: New Technologies Create Global Opportunities.
Paula Ness Speers, Partner and Managing Director at Health Advances, leads the firm’s Global Health practice area, which works with a range of
clients, including non-profit global health organizations and for-profit companies developing products with potential applications in the developing world.
To learn more about our experience in the areas of vaccines and global health, please call Paula Ness Speers at Health
Advances’ Boston area office: 781-647-3435.
07.21.09: Has Point of Care Come of Age?
The logic of POC testing, enabling rapid diagnosis and treatment, has been impeccable for decades.
Nevertheless, relatively few POC tests have become commercial successes. Will a more cost-conscious
healthcare system catalyze or impede the adoption of more POC testing? Which POC innovations will
move the needle? What is the future of POC testing in the US and ROW? Some of the industry's pioneers
joined us for a lively debate on this topic during the year’s AACC in Chicago, IL.
Panelists:
Kristin Pothier, Vice President, Health Advances (Moderator and Presenter)
Kent Lewandrowski, Editor-in-Chief, Point of Care Journal
David Lewis, Executive Director, Morgan Stanley-Research
Robert Kunkler, Divisional Vice President, Business Development, Abbott POC
John McDonough, CEO, T2 Biosystems
Douglas Michels, President and CEO, OraSure Technologies
Clinton Severson, Chairman, President and CEO, Abaxis
learn about Health Advances’ expertise in diagnostics and discovery tools and read our latest publications.
06.09.09: Consumer Genetics Show
Philina Lee, PhD, Associate at Health Advances, will address the challenges of biomarker
commercialization at the First Annual Consumer Genetics Show at the Hynes Convention Center
in Boston, June 9-11, 2009. This premier genetics show will gather companies and
organizations involved in DTC genetic testing, genetic research, healthcare, and
law to discuss issues facing the field: best practices, how to navigate the healthcare
system, scientific and technological advances, legal and regulatory challenges, and more.
learn more about Health Advances’ expertise in complex diagnostics and read about our latest publications.
04.22.09: BIOMEDevice Forum
Kristin Pothier, Vice President and Susan Posner, Vice President participated in the
BIOMEDevice Forum, New England's premier executive-level conference focusing on convergence
and cross-sector collaborations among companies in the biotechnology, medical device, IVD,
and pharmaceutical industries. This two-day event brought together key players involved in
investing, partnering, licensing, and developing business opportunities in the rapidly growing
market for innovative healthcare products.
Drug Delivery and Diagnostics
Kristin Pothier, Vice President, Health Advances (Moderator)
Kristin assembled and led senior executives from Allegro Diagnostics, Genzyme Corporation,
Infinity Pharmaceuticals, SeraCare Life Sciences, and BG Medicine on a panel discussion of “Drug
Delivery and Diagnostics,” exploring how different companies are harnessing the power of
drug/diagnostic convergence to push both innovation in the space and corporate objectives forward.
Joining Kristin on the panel were:
Dan Rippy, President & CEO of Allegro Diagnostics
Joan Keutzer, Vice President, Scientific Affairs, Genzyme Corporation
John Evans, Director of Product Development, Infinity Pharmaceuticals
Michael Steele, Vice President- Business Development, SeraCare Life Sciences
Gregg Mayer, Vice President, Diagnostic Strategy, BG Medicine
Convergent Technologies Present Unique Regulatory and Clinical Challenges
Susan, along with David Fox of Hogan & Hartson LLP and Tom Hutchinson of Davol (CR Bard),
led a discussion on the unique challenges posed by combination products and convergent
technologies in the clinical pathway and regulatory processes. Susan offered her
wide-ranging expertise in the device sector and discussed specific strategies that can be
used along the regulatory and clinical paths to avoid pitfalls and maximize revenues.
03.26.09: Is There a Business Model for Companion Diagnostics?
Kristin Pothier, Vice President, Health Advances, moderated “Is There a Business
Model for Companion Diagnostics?” as part of Windhover’s groundbreaking webinar series, Pharma Business Strategies for Biomarkers. The
webinar provided thought-provoking analysis of the evolving concept of how a biomarker may ultimately become linked to a diagnostic
product opportunity — as a predictive test to select patients more likely to respond to a drug or class of drugs, or as a way to monitor
a response to one. But diagnostics development costs are soaring with greater demands for validation from prospective clinical trials,
and pharma companies have been reluctant to support these efforts. Where are diagnostics companies turning for support and funding? Which
high-value opportunities can sustain a business? Is collaboration the answer, and if so, in what form?
Joining Kristin were Mickey Urdea, CEO of Tethys Bioscience; Rosanne Welcher, PhD, MBA General Manager & VP, R&D of The Dako Group;
Iain Miller, Senior Director, Oncology Strategy and Theranostics, BioMérieux; and Peter
Collins, Senior Vice President of Business Development, DxS
see webinar presentation (PDF: 318KB)
02.26.09: Due Diligence – The Un-sung Hero in the Deal Process
Marie Schiller, Partner at Health
Advances, shared her views on the deal process at a meeting of the Massachusetts
Biotech Council (MBC) in Cambridge, MA. Marie was joined by panelists from the pharmaceutical
industry to discuss due diligence in the transaction process, including buyer and seller
perspectives and best practices. Marie’s expertise in guiding corporations through
business and scientific analyses on product development, market positioning, and corporate
strategy as well as her M&A experience complemented insights from these industry panelists:
Janice Olson, VP of Program Management, Genzyme; Young T. Kwon, Director, New Ventures and
Business Development, Biogen Idec; Philip T. Chase, VP of Legal, Alnylam Pharmaceuticals, Inc.;
and Clare Fisher, Senior Director, Oncology Business Development, Genzyme Corporation.
|
|
 |
|
|
|
|
